Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis.
Alexandra GarciaEmilie DugastSita ShahJérémy MorilleChristine Lebrun-FrénayEric ThouvenotJérôme De SèzeEmmanuelle Le PageSandra VukusicAude MauroussetEric BergerOlivier CasezPierre LabaugeAurélie RuetCatarina RaposoFabien BakdacheRégine BuffelsFabienne Le FrèreArnaud B NicotSandrine WiertlewskiPierre-Antoine GourraudLaureline BerthelotDavid-Axel LaplaudPublished in: Neurology(R) neuroimmunology & neuroinflammation (2023)
Our study provides novel insights into the mode of action of anti-CD20, pointing toward the role of EM T cells, particularly a subset of CD8 T cells expressing CCR5.